Name: MC-VC-PABC-DNA31
Brand: BOC Sciences
Rating: 5 (1 reviews)

IUPAC Name

[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-30-[4-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methoxycarbonylamino]piperidin-1-yl]-2,6,15,17-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-23,32,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.14,7.05,36.026,35.028,33]octatriaconta-1,3,5,9,19,21,25,28,30,33,35-undecaen-13-yl] acetate

Canonical SMILES

CC1C=CC=C(C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C(C(O5)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCC(CC7)NC(=O)OCC8=CC=C(C=C8)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCCCCN9C(=O)C=CC9=O)O3)C

InChI

InChI=1S/C77H96N10O21/c1-38(2)60(83-54(90)20-13-12-14-31-87-55(91)25-26-56(87)92)74(100)82-50(19-16-30-79-75(78)101)73(99)80-47-23-21-46(22-24-47)37-104-76(102)81-48-27-32-86(33-28-48)49-35-51(89)61-53(36-49)107-70-62(84-61)57-58-66(95)44(8)69-59(57)71(97)77(10,108-69)105-34-29-52(103-11)41(5)68(106-45(9)88)43(7)65(94)42(6)64(93)39(3)17-15-18-40(4)72(98)85-63(70)67(58)96/h15,17-18,21-26,29,34-36,38-39,41-43,48,50,52,60,64-65,68,93-95,97H,12-14,16,19-20,27-28,30-33,37H2,1-11H3,(H,80,99)(H,81,102)(H,82,100)(H,83,90)(H,85,98)(H3,78,79,101)/b17-15+,34-29+,40-18-/t39-,41+,42+,43+,50-,52-,60-,64-,65+,68+,77-/m0/s1

Solubility

10 mm in DMSO

Appearance

Solid

Shelf Life

0-4°C for short term (days to weeks), or -20°C for long term (months).

Shipping

Room temperature, or blue ice upon request.

Storage

Store at -5°C,keep in dry and avoid sunlight.

Form

Solid

MC-VC-PABC-DNA31, a potent linker-drug conjugate, is a cornerstone in targeted cancer therapies, blending a powerful drug with a specific delivery mechanism. Here are four key applications of MC-VC-PABC-DNA31:

Targeted Drug Delivery: Serving as an innovative carrier, MC-VC-PABC-DNA31 transports cytotoxic drugs directly to cancer cells, all while minimizing harm to healthy tissues. By tethering a therapeutic agent to a targeting moiety, the conjugate selectively binds to overexpressed receptors on tumor cells. This targeted strategy amplifies drug effectiveness while mitigating systemic toxicity.

Antibody-Drug Conjugates (ADCs) Development: MC-VC-PABC-DNA31 assumes a pivotal role in crafting ADCs tailored to combat diverse cancer types. The conjugate harnesses a stable linker to unleash the drug within the cancer cell milieu.

Pharmacokinetic Studies: The MC-VC-PABC-DNA31 linker becomes a linchpin in unraveling the pharmacokinetics of drug conjugates, furnishing invaluable insights into their absorption, distribution, metabolism, and excretion. Through scrutinizing these facets, researchers can fine-tune the application of linker-drug conjugates for optimal therapeutic results.